2023-05-02 08:15:43 ET
German biotech Immatics N.V. ( NASDAQ: IMTX ) added ~30% in the pre-market Tuesday after announcing interim data from an ongoing Phase 1b trial for its IMA203 TCR-T monotherapy in heavily pre-treated patients with solid tumors as a last-line option.
According to the company, the update represented 11 patients with recurrent and/or refractory solid cancers in the dose expansion Cohort A of the trial.
As of the data cut-off on April 4, 2023, they indicated a confirmed objective response rate (ORR) of 67% (6/9) across multiple tumor types at Month 3, an improvement from 64% (7/11) initial ORR at week 6.
There were two confirmed partial responses (cPR) ongoing at more than nine months and three additional partial responses ongoing at data cut-off.
Patients had received a mean of ~4 lines of prior systemic treatments, including all available standard-of-care therapies.
On the safety front, as of the data cut, ten patients (91%) had a low to moderate (Grade 1-2) cytokine release syndrome (CRS), and the treatment-emergent adverse events (TEAEs) were in line with those expected for cell therapies.
The next data update from all three IMA203 Phase 1b Cohorts and the company’s plans to take PRAME TCR-T monotherapy towards pivotal studies is scheduled for Q4 2023.
More on Immatics
- Immatics jumps 11% after early Phase 1 data for cancer candidate
- Immatics: German Small-Cap Developer Of TCR Therapies
For further details see:
Immatics climbs 30% after early Phase 1 data for solid tumor therapy